Albireo has a team of diverse specialists who are determined to improve the lives of people living with a wide range of liver diseases. Find out more.
Location: United States, Massachusetts, Boston
Total raised: $24M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | TPG | tpg.com |
| - | TVM Capita... | tvm-lifesc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.02.2023 | - | $24M | TVM Capita... |
Mentions in press and media 20
| Date | Title | Description |
| 01.02.2023 | TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc. | /EIN News/ -- Recurv is the 8th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund Recurv is developing novel taxane, RP-001, against solid tumors RP-001 delivered in nano-emulsion formulation, f... |
| 01.02.2023 | TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc. | - |
| 01.02.2023 | TVM Capital Life Science announces up to USD 24 million investment in oncology company, Recurv Pharma, Inc. | Recurv is the 8th early-stage or product focused company (PFC) investment for TVM Life Science Innovation II Fund Recurv is developing novel taxane, RP-001, against solid tumors RP-001 delivered in nano-emulsion formulation, focusing drug... |
| 16.08.2022 | Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel | PETACH TIKVAH, Israel, Aug. 16, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansio... |
| 06.01.2022 | Albireo Increases 2021 Bylvay (odevixibat) Sales Guidance | BOSTON - Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, updated guidance for Bylvay net sales, cash and the two Phase 3 clinical studies. Global Bylvay net sales in 2021 are expected... |
| 05.01.2022 | Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance | – Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M – Unaudited cash of at least $248M, updates guidance with cash into 2024 – BOLD Phase 3 study in biliary atresia is over 50% enrolled – ASSERT Phase 3 study in Alagille ... |
| 05.01.2022 | Albireo Pharma : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K | Albireo Increases 2021 BylvayTM(odevixibat) Sales Guidance - Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M - Unaudited cash of $254M, updates guidance with cash into 2024 - BOLD Phase 3 study in biliary atresia is ove... |
| 05.01.2022 | Albireo Pharma : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K/A | Albireo Increases 2021 BylvayTM(odevixibat) Sales Guidance - Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M - Unaudited cash of at least $248M, updates guidance with cash into 2024 - BOLD Phase 3 study in biliary atres... |
| 16.11.2021 | Albireo Pharma : Post-AASLD Business Update | Post-AASLD Business Update November 16, 2021 (Nasdaq: ALBO) For Media & Investors Only ©2021 Albireo Pharma, Inc. All rights reserved Forward Looking Statements This presentation includes "forward-looking statements" within th... |
| 12.10.2021 | CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan | TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed by Singapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients i... |
Show more